Author:
Wei Jian-Hao,Qian Xue-Qin,Wan Yan-Min,Zhao Xiao-Kai,Zhang Chun-Yan,Guo Wei,Zhu Zhao-Qin
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Walzl G, McNerney R, du Plessis N, Bates M, McHugh TD, Chegou NN, Zumla A. Tuberculosis: advances and challenges in development of new diagnostics and biomarkers. Lancet Infect Dis. 2018;18(7):e199–210.
2. Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger CM, Schumacher SG, Steingart KR. Xpert((R)) MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev. 2018;8(8):CD012768.
3. Rufai SB, Singh A, Singh J, Kumar P, Sankar MM, Singh S, Team TBR. Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. J Infect. 2017;75(2):125–31.
4. Liu XH, Xia L, Song B, Wang H, Qian XQ, Wei JH, Li T, Xi XH, Song YL, Li SQ, et al. Stool-based Xpert MTB/RIF ultra assay as a tool for detecting pulmonary tuberculosis in children with abnormal chest imaging: a prospective cohort study. J Infect. 2021;82(1):84–9.
5. Sikhondze W, Dlamini T, Khumalo D, Maphalala G, Dlamini S, Zikalala T, Albert H, Wambugu J, Tayler-Smith K, Ali E, et al. Countrywide roll-out of Xpert(®) MTB/RIF in Swaziland: the first three years of implementation. Public Health Action. 2015;5(2):140–6.